buyModerate

James E Flynn bought $30M of LRMR

director, owner, other at Larimar Therapeutics, Inc.. 9,375,000 shares at an average of $3.20, traded Jul 31, 2025, filed Aug 4, 2025.

Conviction score

Value

$30M

9,375,000 shares

Holdings after

7,321,129

+152% from before

From 52-week low

no price yet

From 52-week high

no price yet

Score components

Role
Director
+15
Trade size
$30.0M at market
+25
Relative to holdings
Holdings up 152%
+10
Price context
No price history yet
0
Cluster
No other insider buying within 14 days
0
Repeat buying
First buy in 90 days
0
Track record
Too few past buys to judge (0 with prices)
0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001193805-25-001155, as filed. Open on EDGAR

Date	Transaction	Shares	Price	Value	Holdings after	Filed
Jul 31, 2025	POpen-market purchase Common Stockindirect: Through Deerfield Private Design Fund III, L.P.	+3,387,529	$3.20	$11M	9,538,918	Aug 4, 2025
Jul 31, 2025	POpen-market purchase Common Stockindirect: Through Deerfield Private Design Fund IV, L.P.	+3,387,539	$3.20	$11M	9,538,945	Aug 4, 2025
Jul 31, 2025	POpen-market purchase Common Stockindirect: Through Deerfield Healthcare Innovations Fund, L.P.	+2,599,932	$3.20	$8.3M	7,321,129	Aug 4, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.